{"qas": [{"question": "Who regulates antibiotic approval?", "id": "5733d91e4776f4190066134a", "answers": [{"text": "FDA", "answer_start": 77}], "is_impossible": false}, {"question": "What could help to spur pharmaceuticals to make new antibiotics?", "id": "5733d91e4776f4190066134b", "answers": [{"text": "economic incentives", "answer_start": 107}], "is_impossible": false}, {"question": "What are resistant bacteria called in the media?", "id": "5733d91e4776f4190066134c", "answers": [{"text": "superbugs", "answer_start": 332}], "is_impossible": false}, {"question": "Who is a director at the Pew Charitable Trusts?", "id": "5733d91e4776f4190066134d", "answers": [{"text": "Allan Coukell,", "answer_start": 763}], "is_impossible": false}, {"plausible_answers": [{"text": "FDA", "answer_start": 77}], "question": "Who regulates infection approval?", "id": "5a65eeb2c2b11c001a425e0b", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "economic incentives", "answer_start": 107}], "question": "What could help to spur pharmaceuticals to make new infections?", "id": "5a65eeb2c2b11c001a425e0c", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "Allan Coukell", "answer_start": 763}], "question": "Who is a director at the FDA?", "id": "5a65eeb2c2b11c001a425e0d", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "The CDC", "answer_start": 475}], "question": "Who will monitor the use of economic incentives?", "id": "5a65eeb2c2b11c001a425e0e", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "Antibiotic Development to Advance Patient Treatment", "answer_start": 195}], "question": "Who aims to fast track healthcare professionals?", "id": "5a65eeb2c2b11c001a425e0f", "answers": [], "is_impossible": true}], "context": "Possible improvements include clarification of clinical trial regulations by <a0_0><b4_0>FDA<b4_0/><a0_0/>. Furthermore, appropriate <a1_0><b5_0>economic incentives<b5_0/><a1_0/> could persuade pharmaceutical companies to invest in this endeavor. <b8_0>Antibiotic Development to Advance Patient Treatment<b8_0/> (ADAPT) Act aims to fast track the drug development to combat the growing threat of '<a2_0>superbugs<a2_0/>'. Under this Act, FDA can approve antibiotics and antifungals treating life-threatening infections based on smaller clinical trials. <b7_0>The CDC<b7_0/> will monitor the use of antibiotics and the emerging resistance, and publish the data. The FDA antibiotics labeling process, 'Susceptibility Test Interpretive Criteria for Microbial Organisms' or 'breakpoints', will provide accurate data to healthcare professionals. According to <a3_0><b6_0>Allan Coukell<b6_0/>,<a3_0/> senior director for health programs at The Pew Charitable Trusts, \"By allowing drug developers to rely on smaller datasets, and clarifying FDA's authority to tolerate a higher level of uncertainty for these drugs when making a risk/benefit calculation, ADAPT would make the clinical trials more feasible.\""}